Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9333183 | 0.92 | — | — | |
| SCHEMBL1657231 | 0.92 | — | — | |
| SCHEMBL5519959 | 0.92 | — | — | |
| SCHEMBL4557350 | 0.92 | — | — | |
| SCHEMBL22268 | 0.92 | — | — | |
| SCHEMBL9503031 | 0.88 | LMNA (0.61) | LMNAALDH1A1THRBUSP2CYP3A4 | |
| Glycerin SCHEMBL269832 | 0.84 | LMNA (0.82) | LMNAALDH1A1THRBTSHRTDP1 | |
| Glycerin SCHEMBL9121981 | 0.84 | LMNA (0.82) | LMNAALDH1A1THRBTSHRTDP1 | |
| Glycerin SCHEMBL6025187 | 0.84 | LMNA (0.82) | LMNAALDH1A1THRBTSHRTDP1 | |
| Glycerin SCHEMBL1903108 | 0.84 | LMNA (0.82) | LMNAALDH1A1THRBTSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140328794-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2267018-A2 | Binding polypeptides for B lymphocyte stimulator protein (BLyS) | Human Genome Sciences, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2267019-A2 | Binding polypeptides for B lymphocyte stimulator protein (BLyS) | Human Genome Sciences, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7179629-B2 | Regulation of human serine/threonine kinase | BAYER HEALTHCARE AG (DE) | 2007-02-20 | — | — | US | disclosed |
| US-20050214768-A1 | Regulation of human serine/threonine kinase | BAYER HEALTHCARE AG (DE) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328794-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, IAPP | LMNA 2320/4885ALDH1A1 2321/4885THRB 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.